TauRx Completes US$135m Financing Round to Support Phase 3 Clinical Trials Program in Alzheimer’s and Frontotemporal Dementia
Oct 07 - 2015 09:27 PM
ABERDEEN, Scotland and SINGAPORE, 07 October 2015 – TauRx Pharmaceuticals Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer’s disease, today announced the completion of the final tranche of a US$135m equity financing that it launched in March.
TauRx Publishes Six New Journal Articles
Jun 01 - 2015 06:00 AM
With the publication of a key article in The Journal of Biological Chemistry, TauRx Pharmaceuticals Ltd. continues to build a growing body of evidence supporting the rationale for tau aggregation inhibition in the treatment of neurodegenerative diseases such as Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD). This latest of six connected papers, five of them published in the past six months, describes the robust scientific research programme behind the development of LMTX, the second-generation tau aggregation inhibitor (TAI) currently in three large global Phase 3 clinical trials.
First Evidence of Potential Efficacy of Tau Aggregation Inhibitor Therapy in Alzheimer’s Disease
Jan 19 - 2015 06:00 AM
The Journal of Alzheimer’s Disease has published today the results of the first clinical trial of a Tau Aggregation Inhibitor (TAI) in Alzheimer’s disease (AD). This Phase II clinical trial, conducted by TauRx Therapeutics Ltd (a Singapore incorporated spinout from the University of Aberdeen), provided the basis and rationale for subsequent Phase III clinical trials of a TAI in AD currently in progress.
TauRx Therapeutics Achieves Enrolment Target for Second Phase III Clinical Trial of LMTX™ in Alzheimer’s Disease
Sep 22 - 2014 10:28 AM
TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer’s disease into the second of its two Phase III clinical trials of LMTX™, a tau aggregation inhibitor, for the treatment of Alzheimer’s disease.
TauRx Therapeutics Achieves Enrolment Target in the First of its Two Phase III Clinical Trials of LMTX™ in Alzheimer’s Disease
Jul 15 - 2014 06:00 AM
TauRx Therapeutics Ltd today announced it has achieved its target enrolment of 833 subjects into one of its two ongoing multi-centre Phase III clinical trials of LMTX™, a tau aggregation inhibitor, for the treatment of Alzheimer’s Disease [AD].